The effect of prednisolone on the rat phrenic nerve-diaphragm preparation treated with hemicholinium.

doi:10.1016/0014-2999(74)90184-8

Paper

The effect of prednisolone on the rat phrenic nerve-diaphragm preparation treated with hemicholinium.

Published Nov 1, 1974 · E. Wolters, R. S. Leeuwin, G. V. van Wijngaarden

European journal of pharmacology

Q1 SJR score

23

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

Prednisolone can prevent the blocking effect of hemicholinium-3 in a rat phrenic nerve-diaphragm preparation, potentially benefiting myasthenia gravis patients.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

The effect of prednisolone on the rat phrenic nerve-diaphragm preparation treated with hemicholinium.

Sign up to use Study Snapshot

References

Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.

Gradually increasing prednisone doses in myasthenia gravis treatment can prevent early weakening and extend the usefulness of steroid therapy to a larger group of patients.

Treatment of myasthenia gravis with prednisone.

Prednisone treatment can improve muscle strength in patients with myasthenia gravis, but may require more frequent treatment at the beginning.

Benefit from alternate-day prednisone in myasthenia gravis.

Alternate-day oral prednisone can improve muscle function and potentially lead to complete remission in myasthenia gravis patients.

MY ASTHENIA GRAVIS: A NEW HYPOTHESIS OF THE PATHOGENESIS AND A NEW FORM OF TREATMENT

Myasthenia gravis may result from abnormalities in the total lower alpha motor neuron, potentially affecting the metabolic machinery of the LMN soma, leading to partial dysfunction of muscle fibers.

Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment.

Massive doses of ACTH can often bring about remission in severe myasthenia patients, but the initiation of treatment carries danger due to transient increase of weakness, and all have lamented the brevity of remission which might occur.

Citations